Study on Olaparib Plus Abiraterone as First-line Treatment for Men with Advanced Prostate Cancer

Inclusion Criteria

• Able to give informed consent and follow study requirements.
• Men aged 18 or older (19 in South Korea).
• Diagnosed with prostate cancer that has spread.
• Cancer must be resistant to standard hormone therapy.
• Must be receiving ongoing hormone therapy to lower testosterone levels.
• Suitable for abiraterone treatment with evidence of cancer progression.
• Normal organ and bone marrow function.
• Good overall health with a performance status of 0-1.
• Life expectancy of at least 6 months.
• Must provide a tumor sample for analysis.
• Must use effective contraception during and after treatment.

Exclusion Criteria

• Have another cancer that has progressed or needed treatment in the last 5 years.
• Have certain blood disorders like myelodysplastic syndrome or acute myeloid leukemia.
• Have significant heart disease or planned heart surgery.
• Have uncontrolled high blood pressure.
• Have uncontrolled hormone-related disorders.
• Have active infections or conditions that prevent steroid use.
• Have severe side effects from previous cancer treatments.
• Have brain metastases or spinal cord compression unless stable.
• Cannot swallow pills or have digestive issues affecting medication absorption.
• Have compromised immune system or active hepatitis infection.
• Have previously taken PARP inhibitors or certain other cancer drugs.
• Have taken strong medications that affect liver enzymes recently.
• Have had major surgery recently or participated in another clinical trial recently.
• Have allergies to study drugs or their components.
• Are involved in the study's planning or conduct.